27th Oct 2016 11:25
LONDON (Alliance News) - Shire PLC Thursday said that it presented data from a phase II study of its investigational antiviral agent maribavir at the Infectious Disease Week conference in New Orleans, Louisiana.
The study is investigating maribavir in the treatment of patients with cytomegalovirus infection undergoing hematopoietic stem cell transplant or solid organ transplant who are resistant or refractory to ganciclovir or foscarnet, drugs currently used to treat these infections.
In the study, 67% of the patients treated with varying doses of maribavir had no detectable levels of the virus in their blood plasma within six weeks of starting treatment.
"Shire has a strong commitment to continuing research for small and underserved patient populations. We are extremely encouraged by these Phase 2 results, and will be progressing forward with our Phase 3 research program to further evaluate this agent?s efficacy and safety in these patients," said Shire Head of Global Clinical Development Howard Mayer in a statement.
Shares in Shire were up 0.3% at 4,913.50 pence Thursday afternoon.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Shire